February 13, 2025
Elite Diagnostic Limited (ELITE)
Unaudited Financials for the Six Months Ended December 31, 2024:
Elite Diagnostic Limited (ELITE) reported an 8% increase in income, totalling $401.73 million for the six months ended December 31, 2024, compared to $371.97 million in the corresponding period last year. Income for the second quarter increased by 13%, closing at $198.86 million compared to $175.74 million for the comparable quarter of 2023.
Direct costs amounted to $109.36 million (2023: $103.98 million), representing a 5% year-over-year increase. Consequently, gross profit increased by 9% to $292.36 million compared to $267.99 million for the six months ended December 31, 2023. The company booked a gross profit of $149.50 million for the second quarter versus $129.95 million reported for the similar quarter of 2023.
Administrative expenses increased by 16%, closing at $207.81 million (2023: $179.72 million), while depreciation and amortization increased by 10%, from $76.33 million in 2023 to $84.33 million in the period under review. As a result, operating profit for the six months ended December 31, 2024, amounted to $222,000, a 98% decrease relative to $11.94 million reported in 2023.
Foreign exchange gain for the six months ended December 31, 2024, amounted to $1.10 million, relative to the foreign exchange loss of $1.24 million reported in 2023. Foreign exchange gain for the second quarter amounted to $1.00 million (2023: foreign exchange loss of $944,061). Finance costs totalled $19.01 million, a 25% decrease from the corresponding period last year (2023: $25.27 million).
Loss before tax for the six months ended December 31, 2024, amounted to $17.65 million, a 22% increase relative to $14.52 million reported in 2023. Loss before tax for the second quarter amounted to $6.21 million (2023: $9.04 million).
Net loss for the six months amounted to $17.65 million, a 22% increase from the $14.52 million reported in 2023. For the second quarter, net loss was $6.21 million (2023: $9.04 million).
Consequently, loss per share for the six months amounted to $0.05 (2023: LPS: $0.04), while loss per share for the quarter totalled $0.02 (2023: LPS: $0.03).
The twelve-month trailing EPS was $0.07, and the number of shares used in these calculations was 353,400,000.
Notably, ELITE’s stock price closed the trading period on February 13, 2025, at $1.68, with a corresponding P/E ratio of 25.78x.
Balance Sheet Highlights:
The company’s assets totalled $999.93 million (2023: $1.05 billion). This decrease in total assets was attributable to the right of use of assets, which amounted to $82.89 million (2023: $121.72 million). Property, plant, and equipment also contributed to the decrease, equating to $714.78 million (2023: $752.06 million).
Shareholders’ equity was $493.33 million (2023: $469.94 million), representing a book value per share of $1.40 (2023: $1.33).
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
